CA2375378C - Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines - Google Patents

Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines Download PDF

Info

Publication number
CA2375378C
CA2375378C CA002375378A CA2375378A CA2375378C CA 2375378 C CA2375378 C CA 2375378C CA 002375378 A CA002375378 A CA 002375378A CA 2375378 A CA2375378 A CA 2375378A CA 2375378 C CA2375378 C CA 2375378C
Authority
CA
Canada
Prior art keywords
carnitine
alkanoyl
pharmacologically acceptable
acceptable salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002375378A
Other languages
English (en)
Other versions
CA2375378A1 (fr
Inventor
Arduino Arduini
Alessandro Peschechera
Paolo Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/fr
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2375378A1 publication Critical patent/CA2375378A1/fr
Application granted granted Critical
Publication of CA2375378C publication Critical patent/CA2375378C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique. Cette composition comprend un produit abaissant le taux de lipides, comme la lovastatine, la simvastatine, la pravastatine et la fluvastatine et la L-carnitine ou L-carnitine alcanoyle. Cette composition présente l'avantage de conserver l'efficacité d'un produit abaissant le taux de lipides et d'être sensiblement dépourvu d'effets toxiques ou d'effets secondaires propres à ce type de médicaments.
CA002375378A 1999-06-08 2000-06-05 Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines Expired - Fee Related CA2375378C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
US60/138,008 1999-06-08
EP99830415.8 1999-06-30
EP99830415A EP1064943B1 (fr) 1999-06-30 1999-06-30 Combinaison ayant une activité hypolipémiante substantiellement dénuée des effets toxiques ou effets secondaires causés par les médicaments à activité hypolipémiante
PCT/EP2000/005091 WO2000074675A1 (fr) 1999-06-08 2000-06-05 Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines

Publications (2)

Publication Number Publication Date
CA2375378A1 CA2375378A1 (fr) 2000-12-14
CA2375378C true CA2375378C (fr) 2009-08-11

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375378A Expired - Fee Related CA2375378C (fr) 1999-06-08 2000-06-05 Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines

Country Status (10)

Country Link
JP (1) JP2003501385A (fr)
KR (1) KR100725263B1 (fr)
AU (1) AU782188B2 (fr)
CA (1) CA2375378C (fr)
CZ (1) CZ20014218A3 (fr)
HU (1) HUP0201597A3 (fr)
MX (1) MXPA01012644A (fr)
PL (1) PL197899B1 (fr)
SK (1) SK285900B6 (fr)
WO (1) WO2000074675A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678746C (fr) * 2007-02-27 2018-05-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition a utiliser pour le traitement du diabete de type 2
SG10201507488RA (en) * 2007-03-21 2015-10-29 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
US20110052556A1 (en) 2008-02-29 2011-03-03 Biolab Sanus Farmaceutical Ltda Pharmaceutical composition comprising racetam and carnitine and process for its preparation
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
CA2007983C (fr) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 avec inhibiteurs de la hmg-coa
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico

Also Published As

Publication number Publication date
KR20020025066A (ko) 2002-04-03
HUP0201597A3 (en) 2003-04-28
HUP0201597A2 (en) 2002-09-28
AU782188B2 (en) 2005-07-07
JP2003501385A (ja) 2003-01-14
CA2375378A1 (fr) 2000-12-14
PL197899B1 (pl) 2008-05-30
SK17152001A3 (sk) 2002-03-05
SK285900B6 (sk) 2007-10-04
MXPA01012644A (es) 2002-07-22
PL352106A1 (en) 2003-07-28
KR100725263B1 (ko) 2007-06-07
CZ20014218A3 (cs) 2002-04-17
AU5969700A (en) 2000-12-28
WO2000074675A1 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
SK284142B6 (sk) Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
KR20050012771A (ko) 치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
CA2007983C (fr) Coenzyme q10 avec inhibiteurs de la hmg-coa
JPH04225916A (ja) 脂血障害の治療用組成物
US9642860B2 (en) Combinations of corroles and statins
CA2375378C (fr) Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
EP1064943B1 (fr) Combinaison ayant une activité hypolipémiante substantiellement dénuée des effets toxiques ou effets secondaires causés par les médicaments à activité hypolipémiante
RU2002106751A (ru) Лечение мигрени с помощью введения α-липоевой кислоты или ее производных
ZA200201637B (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof.
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
US20050182106A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CA2678746C (fr) Composition a utiliser pour le traitement du diabete de type 2
EP1699448A2 (fr) Procede d'administration d'acide 3,3,14,14 tetramethyl hexadecane 1,16 dioique
CN113134086A (zh) 一种降血脂的药物组合物
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
EP1358879A1 (fr) Agents hypolipemiants
Hamilton-Craig et al. Statin-fibrate combination therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170605